Back to Search Start Over

Apelin, a promising target for type 2 diabetes treatment?

Authors :
Claude Knauf
Isabelle Castan-Laurell
Philippe Valet
Cédric Dray
Oxana Kunduzova
Institut des Maladies Métaboliques et Cardiovasculaires (I2MC)
Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)
Simon, Marie Francoise
Source :
Trends Endocrinol Metab, Trends Endocrinol Metab, 2012, 23 (5), pp.234-41. ⟨10.1016/j.tem.2012.02.005⟩
Publication Year :
2012
Publisher :
Elsevier BV, 2012.

Abstract

International audience; Insulin resistance is a main feature of obesity and type 2 diabetes mellitus (T2DM). Several mechanisms linking obesity to insulin resistance have been proposed. Adipose tissue modulates metabolism by secreting a variety of factors, which exhibit altered production during obesity. Apelin, a small peptide present in a number of tissues and also produced and secreted by adipocytes, has emerged as a new player with potent functions in energy metabolism, and in insulin sensitivity improvement. In this review, we describe the various metabolic functions that are affected by apelin and we present an integrated overview of recent findings that collectively propose apelin as a promising target for the treatment of T2DM.

Details

ISSN :
10432760
Volume :
23
Database :
OpenAIRE
Journal :
Trends in Endocrinology & Metabolism
Accession number :
edsair.doi.dedup.....b76af2cf08cbdf284dcb99b0a05996b3